

Title (en)  
ALLOGENEIC CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES

Title (de)  
ALLOGENE, ZELLULÄRE IMMUNOGENE, DIE ALS KREBSIMPFSTOFF EINSETZBAR SIND

Title (fr)  
IMMUNOGENES CELLULAIRES ALLOGENIQUES UTILES COMME VACCINS CONTRE LE CANCER

Publication  
**EP 1100544 A4 20030115 (EN)**

Application  
**EP 99933855 A 19990708**

Priority  
• US 9915594 W 19990708  
• US 9396598 P 19980724

Abstract (en)  
[origin: WO0004927A1] A cellular immunogen is provided for immunizing a host against the effects of the product of a target proto-oncogene, where the overexpression of the target proto-oncogene is associated with a malignancy. The cellular immunogen comprises allogeneic (with respect to the host) cells which have been transfected with at least one transgene construct comprising a transgene cognate to the target proto-oncogene and a strong promoter to drive the expression of the transgene in the transfected cells. The transgene encodes a gene product which induces host immunoreactivity to host self-determinants of the product of the target proto-oncogene gene. The transgene may comprise, for example, wild-type or mutant retroviral oncogene DNA cognate to the target proto-oncogene; or wild-type or mutant proto-oncogene DNA of a species different from the host species. The cellular immunogen may be prepared from allogeneic donor cells, e.g. skin fibroblasts, which are stably or transiently transfected with the transgene construct containing the cognate transgene. The donor cells transfected with the cognate transgene constructs are then inserted into the body of the host to obtain expression of the cognate transgene in the host.

IPC 1-7  
**A61K 48/00; A01N 63/00; C12N 15/63; C12N 15/85; C12N 15/86; C07H 21/04**

IPC 8 full level  
**A61K 39/00** (2006.01)

CPC (source: EP US)  
**A61K 39/0011** (2013.01 - EP US); **A61K 39/001106** (2018.08 - EP US); **A61K 39/001152** (2018.08 - EP US); **A61K 39/001164** (2018.08 - EP US); **A61K 2039/5156** (2013.01 - EP US); **A61K 2039/53** (2013.01 - EP)

Citation (search report)  
• [Y] WO 9725860 A1 19970724 - ALLEGHENY UNIVERSITY OF THE HE [US], et al  
• [Y] WO 9531107 A1 19951123 - UNIV ILLINOIS [US]  
• [X] JOHNSON P J ET AL: "OVEREXPRESSED PP-60C-SRC CAN INDUCE FOCUS FORMATION WITHOUT COMPLETE TRANSFORMATION OF NIH-3T3 CELLS", MOLECULAR AND CELLULAR BIOLOGY, vol. 5, no. 5, 1985, pages 1073 - 1083, XP009000334, ISSN: 0270-7306  
• [X] BACUS S S ET AL: "TUMOR-INHIBITORY MONOCLONAL ANTIBODIES TO THE HER-2/NEU RECEPTOR INDUCE DIFFERENTIATION OF HUMAN BREAST CANCER CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 52, 1 May 1992 (1992-05-01), pages 2580 - 2589, XP000919492, ISSN: 0008-5472  
• [X] ZHU DAN ET AL: "Overexpression of CD44 in p185-neu-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell adhesion.", ONCOGENE, vol. 12, no. 11, 1996, pages 2309 - 2314, XP009000333, ISSN: 0950-9232  
• [DY] HUANG A Y C ET AL: "ROLE OF BONE MARROW-DERIVED CELLS IN PRESENTING MHC CLASS I-RESTRICTED TUMOR ANTIGENS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 264, 13 May 1994 (1994-05-13), pages 961 - 965, XP002037401, ISSN: 0036-8075  
• See also references of WO 0004927A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0004927 A1 20000203**; AU 4981999 A 20000214; EP 1100544 A1 20010523; EP 1100544 A4 20030115

DOCDB simple family (application)  
**US 9915594 W 19990708**; AU 4981999 A 19990708; EP 99933855 A 19990708